AGPS and asthma: A systematic review and meta-analysis of ADA incidence in > 12,300 patients from 43 studies receiving monoclonal antibody treatment for moderate-to-severe asthma found ADAs in 0–8% of patients (omalizumab 0%; tezepelumab, 1%; mepolizumab, 4%; reslizumab, 4%; dupilumab, 8%; benralizumab, 8%) [49], which is broadly in line with the incidence of treatment-induced astegolimab ADAs seen in the Phase II astegolimab trials.